Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FLXN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLXNFlexion Therapeutics$9.12$9.20$4.30▼$13.66$458.93M1.531.18 million shsN/A7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLXNFlexion Therapeutics0.00%0.00%0.00%0.00%0.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFLXNFlexion Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFLXNFlexion Therapeutics$85.55M5.36N/AN/A($0.34) per share-26.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFLXNFlexion TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFLXNFlexion TherapeuticsN/A4.384.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFLXNFlexion Therapeutics90.01%Insider OwnershipCompanyInsider OwnershipFLXNFlexion Therapeutics9.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFLXNFlexion Therapeutics25750.32 million45.73 millionOptionableFLXN HeadlinesRecent News About These CompaniesWar Robots is coming to alternative storefronts following MY.GAMES and Flexion's collaborationOctober 3, 2024 | pocketgamer.comFlexion wins contract to support CFPB in evaluating financial education contentApril 25, 2024 | finance.yahoo.comFlexion awarded contract to revolutionize Head Start’s Data Management SystemApril 19, 2024 | finance.yahoo.comFlexion Joins AWS Public Sector Partner Program, Enhancing Commitment to Public Sector Software ProjectsApril 11, 2024 | tmcnet.comVIRI Virios Therapeutics, Inc.April 6, 2024 | seekingalpha.comSpyre Therapeutics Inc SYREFebruary 14, 2024 | morningstar.comPFIZER INC's Net WorthFebruary 10, 2024 | benzinga.comFlexion/Extension Fluoroscopy of C-Spine is InadequateJanuary 12, 2024 | medscape.comSpringWorks Therapeutics Stock (NASDAQ:SWTX), Analyst Ratings, Price Targets, PredictionsNovember 24, 2023 | benzinga.comFlexion Mobile: Cuts 2023 sales forecast on softer Q3 - ABGNovember 6, 2023 | nyheter24.seOppo Unveils Find N3: Foldable Phone with Flexion Hinge and Snapdragon 8 Gen 2October 19, 2023 | newsd.inFlexion wins MCADS contract to modernize CMS Claims Handling SystemJuly 11, 2023 | benzinga.comFlexion achieves Select Tier Status within the AWS Partner NetworkJuly 10, 2023 | finance.yahoo.com7 Exercises to Stretch Plantar Flexion MovementJune 10, 2023 | yahoo.comPain Therapeutics conference is taking place in London next weekJune 8, 2023 | pharmaphorum.comFlexion Mobile: Notice of Annual General MeetingMay 31, 2023 | privataaffarer.se2023-2029 Flexion Tires Market Growth Prospects and Countries Analysis | with 91 PagesMay 16, 2023 | marketwatch.comOPPO Find N2 Flip's Flexion Hinge Marks A Breakthrough In Flip Phone ExperienceMay 4, 2023 | finance.yahoo.comProne Leg Flexion Trainers Market Global Outlook and Projection till 2029April 28, 2023 | marketwatch.comAbdominal Flexion Training Device Market Research & Size Analysis 2023-2028April 12, 2023 | marketwatch.comFLXN Company DescriptionsFlexion Therapeutics NASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Will CrowdStrike's Goodwill Strategy Pay Off in Revenue Gains? Options Activity Points to More Volatility for Palantir Stock NVIDIA Stock: Oversold, Undervalued — How Low Can It Go? MicroStrategy Sees Insider Buy-Sell Action in Q1 Buffett’s Next Oil Bet: Why Occidental Is Different Springing Dividends: 3 Dividend Boosters to Watch Now Alibaba Caught in Tariff Crossfire: Is It Time to Buy? Can Solid Biosciences Challenge Sarepta in the DMD Market? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
